On June 27, 2009, Gina Kolata’s article in the New York Times on the too safe nature of funding from the National Institute of Health (NIH) struck a chord for many of us. She opens the article with the following, “Among the recent research grants awarded by the National Cancer Institute is one for a [...]
Men with advanced prostate cancer who develop an adrenal tumor will usually undergo laparoscopic adrenalectomy (removal of the adrenal gland) as a treatment method. Just like with prostate surgery. in some situations surgery might not be the best alternative for an individual man. An individual case was recently completed at the Department of Renal and [...]
A presentation at the ASCO conference in Florida reconfirmed the fact that increased levels of C-reactive protein (CRP) is associated with adverse outcomes (earlier death) in men with castration-resistant prostate cancer (CRPC) treated with docetaxel (taxotere). The study analyzed the baseline serum samples from 119 castrate resistant (CRPC) men enrolled in 6 phase I or [...]
There is a new study that shows that an alpha-particle emitting radiopeptide—radioactive material bound to a synthetic peptide, a component of protein—is effective for treating prostate cancer in mice, according to researchers. The conclusions of this study could eventually (still years away if it also works in men) result in a significant breakthrough in advanced [...]
On Thursday the Senate Appropriations subcommittee on Labor, Health and Human Services, and Education held its FY 2010 NIH budget hearing. There were two particular items of note for the cancer community. When discussing the NIH funding which was received through the economic stimulus package, Senator Harkin questioned if the current two years the NIH [...]